Premium
Programmed death‐1 expression in cutaneous B‐cell lymphoma
Author(s) -
Çetinözman Fatma,
Koens Lianne,
Jansen Patty M.,
Willemze Rein
Publication year - 2014
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/cup.12254
Subject(s) - lymphoma , pathology , germinal center , immunohistochemistry , medicine , marginal zone , cd3 , b cell , antibody , immunology , antigen , cd8
Background Numbers of programmed death‐1 ( PD ‐1) positive T cells have prognostic significance in some types of nodal B‐cell lymphomas, but data on PD ‐1 expression in cutaneous B‐cell lymphoma ( CBCL ) are few. In this study we determined the expression and distribution of PD ‐1 on neoplastic B cells and reactive T cells in skin sections from primary CBCLs . Methods By means of immunohistochemical staining, PD ‐1 expression was investigated in skin biopsies from 10 patients with primary cutaneous marginal zone lymphoma ( PCMZL ), 18 patients with primary cutaneous follicle center lymphoma ( PCFCL ) and 12 patients with primary cutaneous diffuse large B‐cell lymphoma–leg type ( PCDLBCL–LT ). Results Neoplastic B cells were negative for PD ‐1 in all cases, except for two cases of PCDLBCL–LT . The frequency of PD ‐1 + T cells was significantly higher in PCFCL than in PCMZL and PCDLBCL–LT , accounting for 20, 10 and 3% of the total number of infiltrating cells, and 60, 20 and 15% of the total number of CD3 + T cells, respectively. Conclusions PD ‐1 is rarely expressed by the neoplastic B cells in CBCL . High percentages of PD ‐1 + T cells, particularly if found outside germinal centers, support a diagnosis of PCFCL .